Patents Assigned to Icos Corporation
  • Tetracyclic derivatives, process of preparation and use
    Patent number: 6369059
    Abstract: A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen or C1-6 alkyl; R1 represents hydrogen, C1-6alkyl, C2-6alkenyl, C2-6 alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cycloalkylC1-3alkyl, arylC1-3alkyl or heteroarylC1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring  attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3 represents hydrogen or C1-3 alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain.
    Type: Grant
    Filed: August 7, 2000
    Date of Patent: April 9, 2002
    Assignee: ICOS Corporation
    Inventor: Alain Claude-Marie Daugan
  • Fermentation post-sterile additive delivery method and apparatus
    Publication number: 20020039781
    Abstract: A fermentation process post-sterile additive device and method of operation is detailed. The device is used to deliver additive as a heavy-drop mist. The mist covers the entire fermenting batch head surface of the vat broth. This improves mixing and reduces the amount of additive to appropriate introduction levels throughout log phase fermentation, preventing coating of cultivating cells and interference with cell respiration. A steady state growth rate is fostered.
    Type: Application
    Filed: December 4, 2001
    Publication date: April 4, 2002
    Applicant: ICOS Corporation
    Inventor: Drew C. Coleman
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6362213
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 15, 2000
    Date of Patent: March 26, 2002
    Assignee: ICOS Corporation
    Inventor: John J. Gaudino
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Publication number: 20020032224
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Application
    Filed: September 14, 2001
    Publication date: March 14, 2002
    Applicant: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • Phosphodiesterase 10
    Patent number: 6350603
    Abstract: The present invention provides novel human PDE10 polypeptides, polynucleotides encoding the polypeptides, expression constructs comprising the polynucleotides, host cells transformed with the expression constructs; methods for producing PDE10 polypeptides; antisense polynucleotides; and antibodies specifically immunoreactive with the PDE10 polypeptides. The invention further provides methods to identify binding partners of PDE10, and more particularly, binding partners that modulate PDE10 enzyme activity.
    Type: Grant
    Filed: February 23, 1999
    Date of Patent: February 26, 2002
    Assignee: ICOS Corporation
    Inventor: Kate Loughney
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6348602
    Abstract: Novel compounds that are potent and selective inhibitors of PIDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 17, 2000
    Date of Patent: February 19, 2002
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Amy Oliver, Joshua Odingo
  • Seven transmembrane receptors
    Patent number: 6348574
    Abstract: DNA sequences encoding seven novel seven transmembrane receptors and variants thereof are disclosed as well as materials and methods for production of the same by recombinant techniques. Antibody substances specific for each of the seven transmembrane receptors are disclosed as useful for the modulation of the ligand/receptor binding reactions of the receptors.
    Type: Grant
    Filed: June 1, 1998
    Date of Patent: February 19, 2002
    Assignee: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray, Vicki Louise Schweickart
  • ATR-2 cell cycle checkpoint
    Patent number: 6344549
    Abstract: Polynucleotides encoding novel Atr-2 cell cycle checkpoint polypeptides are disclosed, along with expression constructs comprising the polynucleotides, host cells transformed with the expression constructs, methods to make the Atr-2 polypeptides using the host cells, Atr-2 polypeptides, and binding partners of the Atr-2 polypeptides.
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: February 5, 2002
    Assignee: ICOS Corporation
    Inventors: Kate Loughney, Kathleen S. Keegan
  • Macrophage derived chemokine
    Patent number: 6320023
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding a novel human macrophage-derived C-C chemokine designated MDC. Also provided are materials and methods for the recombinant production of the chemokine, and purified and isolated chemokine protein.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 20, 2001
    Assignee: ICOS Corporation
    Inventors: Ronald Godiska, Patrick W. Gray
  • Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
    Patent number: 6313156
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: November 6, 2001
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • N-cinnamoyl derivatives of beta-carboline
    Patent number: 6306870
    Abstract: Carboline derivatives of formula (I), are potent and selective inhibitors of cyclic guanosine 3′,5′-monophoshate specific phosphodiesterase (cGMP specific PDE) and have utility in a variety of therapeutic areas where such inhibition is thought to be beneficial, including the treatment of cardivascular disorders.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: October 23, 2001
    Assignee: ICOS Corporation
    Inventor: Agnes Bombrun
  • Icam-related protein
    Publication number: 20010029293
    Abstract: DNA sequences encoding a novel human intercellular adhesion molecule polypeptide (designated “ICAM-R”) and variants thereof are disclosed along with methods and materials for production of the same by recombinant procedures. Binding molecules specific for ICAM-R and variants thereof are also disclosed as useful in both the isolation of ICAM-R from natural cellular sources and the modulation of ligand/receptor binding biological activities of ICAM-R.
    Type: Application
    Filed: January 3, 2001
    Publication date: October 11, 2001
    Applicant: ICOS Corporation
    Inventors: W. Michael Gallatin, Rosemay Vazeux
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6294561
    Abstract: Novel compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: November 14, 2000
    Date of Patent: September 25, 2001
    Assignee: ICOS Corporation
    Inventors: Kerry W. Fowler, Joshua Odingo
  • Platelet-activating factor acetylhydrolase
    Publication number: 20010021379
    Abstract: The present invention provides purified and isolated polynucleotide sequences encoding human plasma platelet-activating factor acetylhydrolase. Also provided are materials and methods for the recombinant production of platelet-activating factor acetylhydrolase products which are expected to be useful in regulating pathological inflammatory events.
    Type: Application
    Filed: December 4, 2000
    Publication date: September 13, 2001
    Applicant: ICOS Corporation
    Inventors: Lawrence S. Cousens, Christine D. Eberhardt, Patrick Gray, Hai Le Trong, Larry W. Tjoelker, Cheryl L. Wilder
  • Chemokine receptor 88-C
    Patent number: 6268477
    Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, viral infection, AIDS, and other inflammatory conditions.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: July 31, 2001
    Assignee: Icos Corporation
    Inventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
  • Polynucleotides encoding chemokine receptor 88C
    Patent number: 6265184
    Abstract: The present invention provides polynucleotides that encode the chemokine receptors 88-2B or 88C and materials and methods for the recombinant production of these two chemokine receptors. Also provided are assays utilizing the polynucleotides which facilitate the identification of ligands and modulators of the chemokine receptors. Receptor fragments, ligands, modulators, and antibodies are useful in the detection and treatment of disease states associated with the chemokine receptors such as atherosclerosis, rheumatoid arthritis, tumor growth suppression, asthma, and other inflammatory conditions.
    Type: Grant
    Filed: December 20, 1995
    Date of Patent: July 24, 2001
    Assignee: Icos Corporation
    Inventors: Patrick W. Gray, Vicki L. Schweickart, Carol J. Raport
  • Cyclic AMP-specific phosphodiesterase inhibitors
    Patent number: 6258833
    Abstract: Novel pyrrolidine compounds that are potent and selective inhibitors of PDE4, as well as methods of making the same, are disclosed. Use of the compounds in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders, also is disclosed.
    Type: Grant
    Filed: December 23, 1999
    Date of Patent: July 10, 2001
    Assignee: ICOS Corporation
    Inventors: Timothy J. Martins, Kerry W. Fowler, Joshua Odingo, Edward Kesicki, Amy Oliver, Laurence E. Burgess, John J. Gaudino, Zachary S. Jones, Bradley J. Newhouse, Stephen T. Schlacter
  • Creba isoform
    Patent number: 6248532
    Abstract: The present invention relates generally to a novel CREBa polypeptide isoform, polynucleotides encoding the polypeptide, expression constructs comprising the polynucleotides, host cell transformed or transfected with the polynucleotides, methods for producing the polypeptide, and methods to identify inhibitors of binding between the CREBa and other polypeptides or polynucleotides.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: June 19, 2001
    Assignee: ICOS Corporation
    Inventor: Kathleen S. Keegan
  • Treatment method using a cGMP-Specific PDE inhibitor
    Patent number: 6218400
    Abstract: A compound of formula and salts and solvates thereof, wherein R0, R1, and R2 are defined in the specification. A compound of the present invention is a potent and selective inhibitor of cGMP-specific PDE and has utility in a variety of therapeutic areas where such inhibition is beneficial.
    Type: Grant
    Filed: August 24, 1999
    Date of Patent: April 17, 2001
    Assignee: ICOS Corporation
    Inventors: Alain Claude-Marie Daugan, Richard Frederic LaBaudiniere
  • Method to identify proteins which bind to integrin regulatory proteins
    Patent number: 6210914
    Abstract: The present invention provides purified and isolated polynucleotides encoding IRP (Integrin Regulatory Protein) polypeptides which regulate &bgr;2 and &bgr;7 integrins and which are contemplated to participate in integrin signaling and/or recycling pathways. Also provided are methods for identifying modulators of IRP activities and methods for identifying other proteins which interact with IRP polypeptides in signaling pathways. Modulators of IRP interactions are contemplated to be useful, for example, in monitoring and treating inflammatory processes involving leukocytes.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: April 3, 2001
    Assignee: ICOS Corporation
    Inventors: Donald E. Staunton, Brian P. Lispky